Children at risk for dyslexia show differences in brain activity on MRI scans even before they begin learning to read, finds a study at Children’s Hospital Boston. Since developmental dyslexia responds to early intervention, diagnosing children at risk before or during kindergarten could head off difficulties and frustration in school, the researchers say…
More: continued […]
Filed under: Clinical Trials on January 24th, 2012 | No Comments »
The Na-GST-1 antigen, a candidate for the first human hookworm vaccine developed by the Sabin Vaccine Institute (Sabin), has entered a Phase 1 human trial in Brazil, according to Sabin. For the vaccine product development partnership (PDP) headquartered at Sabin, the clinical trial is a considerable achievement. Worldwide, almost 600 million individuals are infected […]
Filed under: Clinical Trials on January 21st, 2012 | No Comments »
An experimental drug for advanced colorectal cancer that available treatments have failed to halt, has shown promise in a clinical trial, says Bayer HealthCare, the company that makes it. The results of the phase III trial show that compared to placebo, regorafenib slowed tumor growth and extended survival…
More: continued here
Filed under: Clinical Trials on January 21st, 2012 | No Comments »
The pharmaceutical company Ferrer has received approval to start phase III human trials of ozenoxacin, formulated as a topical treatment for infectious skin conditions. In February 2012, participants are expected to enter the multicenter, randomized, placebo controlled, parallel, double-blinded superiority clinical study, which is scheduled to complete in 2013…
More: continued here
Filed under: Clinical Trials on January 21st, 2012 | No Comments »
A BMJ survey revealed that over one in ten (13%) UK based scientists or doctors have witnessed that colleagues intentionally changed or fabricated data during their research in order to get published, whilst 6% of respondents reported they are aware of possible research misconduct at their institution, that has not been accurately investigated…
More: continued […]
Filed under: Clinical Trials on January 16th, 2012 | No Comments »
OHSU Knight Cancer Institute study results suggest that more patients than initially thought could potentially be treated with a new class of drugs, PARP inhibitors A constellation of defective proteins suspected in causing a malfunction in the body’s ability to repair its own DNA could be the link scientists need to prove a new class […]
Filed under: Clinical Trials on January 16th, 2012 | No Comments »
Missing data is a serious problem in clinical research given that it distorts the scientific record and prevents clinical decisions from being based on the best evidence available. As part of an in-depth BMJ review on the subject, experts on bmj.com warn that patients can be harmed through missing clinical trial data, leading to unnecessary […]
Filed under: Clinical Trials on January 7th, 2012 | No Comments »
Marinus Pharmaceuticals, Inc., a specialty pharmaceutical company, announced that its neurosteroid ganaxolone which is currently under study for the treatment of partial onset seizures (POS), reported positive data in the open-label extension follow up to the company’s Phase 2 clinical trial. The data reflects the replication of the effects seen in the double-blind study…
More: […]
Filed under: Clinical Trials on January 3rd, 2012 | No Comments »
In the first clinical trial of an injectable vaccine containing trimeric HIV envelope protein (gp140) relevant to the predominant strain of HIV in Africa, researchers from four UK academic centers (St George’s University London, Imperial College, Hull York Medical School (HYMS; University of York) and the Medical Research Council Clinical Trial Unit) and from the […]
Filed under: Clinical Trials on January 3rd, 2012 | No Comments »
Neuralstem, Inc. (NYSE Amex: CUR) announced that it has been approved by the Food and Drug Administration to advance to Phase Ib in its ongoing clinical trial to test its novel neuroregenerative compound, NSI-189, for the treatment of major depressive disorder (MDD). Phase Ib will test the safety and tolerability of the drug in depressed […]
Filed under: Clinical Trials on January 1st, 2012 | No Comments »